Bailey Howard H, Mukhtar Hasan
From the University of Wisconsin Carbone Cancer Center, K4/650 Clinical Science Center, Madison, WI; Department of Dermatology, University of Wisconsin-Madison, Madison, WI.
Am Soc Clin Oncol Educ Book. 2013:92-6. doi: 10.14694/EdBook_AM.2013.33.92.
Green tea, which has higher concentrations of polyphenols than other teas, has been correlated with reduced risk of various malignancies with most data supporting a potential protective role in prostate neoplasia. Preclinical studies over the last 25 years implicate constituent green tea catechins, epigallocatechin-3-gallate (EGCG) being the predominant form, as the main mechanistic ingredient in the observed biologic effects, which vary from proapoptotic effects to inhibition of androgen receptor and signal transduction pathways. There have been few prospective clinical trials of green tea polyphenols (GTP), especially with well-characterized formulations and doses. Although there have been hints of beneficial clinical activity in prostate neoplasia, other studies have raised concerns about the limited bioavailability and very low target-tissue concentrations of GTPs. At present there is no proven role for GTP supplementation in the prevention of genitourinary (GU) malignancies, but novel GTP formulations and further clinical testing may still support a future for GTP supplementation in GU cancer prevention.
绿茶中的多酚含量高于其他茶叶,多项数据表明,饮用绿茶与降低患各种恶性肿瘤的风险相关,多数数据支持其对前列腺肿瘤具有潜在的保护作用。过去25年的临床前研究表明,绿茶成分儿茶素(主要形式为表没食子儿茶素没食子酸酯,即EGCG)是观察到的生物学效应的主要机制成分,这些效应包括促凋亡作用、抑制雄激素受体和信号转导通路等。关于绿茶多酚(GTP)的前瞻性临床试验较少,尤其是针对特征明确的制剂和剂量的试验。尽管有迹象表明GTP对前列腺肿瘤具有有益的临床活性,但其他研究对GTP的生物利用度有限和靶组织浓度极低表示担忧。目前,尚无证据证明补充GTP对预防泌尿生殖系统(GU)恶性肿瘤有作用,但新型GTP制剂和进一步的临床试验仍可能为GTP在GU癌症预防中的应用带来前景。